Company intelligence / Profile preview

Enumeral Biomedical

Cambridge, Massachusetts, United Statesen.wikipedia.org ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Enumeral developed a proprietary immunoprofiling platform to discover monoclonal antibodies targeting immune checkpoint proteins. Its lead programs were pre-clinical PD‑1 antagonists. The company did not advance any candidates into clinical trials before bankruptcy and asset sale.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

ENUM-388D4

Preclinical

Partnerships

Merck Sharp & Dohme Corp.University of Texas MD Anderson Cancer CenterNational Cancer Institute

Beyond the preview

Go deeper on Enumeral Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enumeral Biomedical.

Explore the full profile